Eli Lilly & Co. (NYSE:LLY) updated its FY14 earnings guidance on Wednesday. The company provided earnings per share guidance of $2.77-2.85 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.82, AnalystRatings.NET reports. The company issued revenue guidance of $19.2-19.8 billion, compared to the consensus revenue estimate of $19.60 billion. Eli Lilly & Co. (NYSE:LLY) stock opened at $57.30 in last trading session, and closed at $58.09, trading in the range of $56.55 – $58.20. The stock showed a positive weekly performance of 7.53%.
Markets and analysts eyes are all set on Mylan Inc. (NASDAQ:MYL) which is scheduled to announce its fourth quarter financial results on February 27, 2014 amidst various issues ranging from recalling of drugs made by its subsidiaries to alleged rumors of its merger with Teva Pharmaceuticals Pvt. Ltd.. Mylan, right now, is a stock to concentrate on because of its growing presence in Indian market and its capability to produce various important and helpful drugs. Mylan Inc (NASDAQ:MYL) shares closed at $51.15 on last trade day, by gaining 5.90%. Stock 52 week range is $27.66 – $51.20. Company’s market capitalization is $19.58 billion.
Active Biotech (ACTI) announces that its partner Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), has decided not to proceed to the randomization stage of the planned Libretto trial for the treatment of Relapsing Remitting Multiple Sclerosis, or RRMS, as the current design is no longer aligned with the regulatory strategy. This decision has no impact on other ongoing studies, such as CONCERTO, which are proceeding as planned, or on Teva Pharmaceuticals’ plans to initiate clinical studies in Primary Progressive Multiple Sclerosis, or PPMS. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock advanced 2.34% and finished the last session at $46.74. The EPS of the stock remained 1.49. Company’s market capitalization is $44.29 billion.
Actavis plc Ordinary Shares(NYSE:ACT) reported net revenue increased 59 percent to $2.779 billion for the fourth quarter ended December 31, 2013, compared to $1.75 billion in the fourth quarter 2012. On a non-GAAP basis, diluted earnings per share for the fourth quarter 2013 increased to $3.17, compared to $1.59 per diluted share in the fourth quarter 2012. GAAP loss per share for the fourth quarter 2013 was $0.86, compared to GAAP earnings per diluted share of $0.21 in the prior year period. For the fourth quarter 2013, adjusted EBITDA increased 108 percent to $817.1 million, compared to $393.0 million for the fourth quarter 2012. Cash flow from operations for the fourth quarter of 2013 was $651.7 million and cash and marketable securities were $331.5 million as of December 31, 2013. Actavis plc Ordinary Shares(NYSE:ACT) stock opened at $205.44 in last trading session and closed at $210.56. The 52 week range of the stock is $82.02 – $213.11 and the day range was $203.59 – $213.11.